242 related articles for article (PubMed ID: 31822955)
1. Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
Noguchi Y; Esaki H; Murayama A; Sugioka M; Koyama A; Tachi T; Teramachi H
Eur J Clin Pharmacol; 2020 Feb; 76(2):299-304. PubMed ID: 31822955
[TBL] [Abstract][Full Text] [Related]
2. Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADER.
Ohyama K; Okamoto T; Hori Y
Int J Clin Pharmacol Ther; 2023 Jan; 61(1):16-23. PubMed ID: 36366967
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Rahman MM; Scalese MJ; Hansen RA
Ann Pharmacother; 2017 Jul; 51(7):563-569. PubMed ID: 28166651
[TBL] [Abstract][Full Text] [Related]
4. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
[TBL] [Abstract][Full Text] [Related]
5. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
[TBL] [Abstract][Full Text] [Related]
7. Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases.
Ohyama K; Tanaka H; Shindo J; Shibayama M; Iwata M; Hori Y
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):24-31. PubMed ID: 34622771
[TBL] [Abstract][Full Text] [Related]
8. Association between dipeptidyl peptidase-4 inhibitors and autoimmune disorders: Data mining of the spontaneous reporting system in Japan.
Noguchi Y; Toda Y; Esaki H; Matsuyama T; Tachi T; Tsuchiya T; Teramachi H
Pharmazie; 2019 May; 74(5):305-309. PubMed ID: 31109402
[TBL] [Abstract][Full Text] [Related]
9. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
Yi H; Lee JH; Shin JY
Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.
Béné J; Moulis G; Bennani I; Auffret M; Coupe P; Babai S; Hillaire-Buys D; Micallef J; Gautier S;
Br J Dermatol; 2016 Aug; 175(2):296-301. PubMed ID: 27031194
[TBL] [Abstract][Full Text] [Related]
12. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
Kinoshita S; Hosomi K; Yokoyama S; Takada M
Int J Med Sci; 2020; 17(3):302-309. PubMed ID: 32132864
[No Abstract] [Full Text] [Related]
13. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®.
Carnovale C; Mazhar F; Arzenton E; Moretti U; Pozzi M; Mosini G; Leoni O; Scatigna M; Clementi E; Radice S
Expert Opin Drug Saf; 2019 Nov; 18(11):1099-1108. PubMed ID: 31519110
[No Abstract] [Full Text] [Related]
14. Angioedema Caused by Drugs That Prevent the Degradation of Vasoactive Peptides: A Pharmacovigilance Database Study.
Noguchi Y; Murayama A; Esaki H; Sugioka M; Koyama A; Tachi T; Teramachi H
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884209
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture.
Kajiwara A; Saruwatari J; Sakata M; Morita K; Kita A; Oniki K; Yamamura M; Murase M; Koda H; Hirota S; Ishizuka T; Nakagawa K
Drug Saf; 2013 Oct; 36(10):981-7. PubMed ID: 23743694
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance study of the association between dipeptidyl peptidase-4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS).
Ohyama K; Shindo J; Takahashi T; Takeuchi H; Hori Y
Sci Rep; 2022 Jul; 12(1):13122. PubMed ID: 35907939
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database.
Nagel AK; Ahmed-Sarwar N; Werner PM; Cipriano GC; Van Manen RP; Brown JE
Ann Pharmacother; 2016 Jan; 50(1):27-31. PubMed ID: 26497885
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system.
Lu W; Sun S; Wei J; Thai S; Li D; Tang H; Wang T; Sun L
Int J Clin Pharm; 2020 Oct; 42(5):1364-1368. PubMed ID: 32951183
[TBL] [Abstract][Full Text] [Related]
19. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
[No Abstract] [Full Text] [Related]
20. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
Huang J; Jia Y; Sun S; Meng L
BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
